Compare Snap On Incorporated (SNA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs Tango Therapeutics Inc. — how do they compare? Snap On Incorporated trades at $362.47 (market cap $18.81B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Snap On Incorporated is far larger — about 5× Tango Therapeutics Inc.'s market cap, and Snap On Incorporated pays a 2.68% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Snap On Incorporated for 38 Days and Tango Therapeutics Inc. for 0 Days on average.
| SNA | TNGX | |
|---|---|---|
Market Cap | $18.81B | $3.75B |
Volume | 239,235 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $419.31 | $32.90 |
52-Week Low | $328.69 | $7.50 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $18.45B | $2.77B |
Dividend Yield | 2.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-On Incorporated (SNA) trades at $363.67, up 0.46% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 19.6% and ROE of 17.58%, while Q2 2026 earnings beat estimates. Recent news highlights gross margin expansion and institutional trading activity.
The outlook is supported by analyst consensus with a $449 price target and 66.7% buy ratings, but risks include valuation premiums and mixed segment trends. Earnings growth and RCI initiatives remain key catalysts, though integration costs and softer OEM demand pose near-term challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
